VolitionRX/VNRX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About VolitionRX

VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

Ticker

VNRX

Sector

Healthcare

Trading on

AMEX

Industry

Biotechnology & Drugs

CEO

Cameron Reynolds

Employees

110

Headquarters

Henderson, United States

VolitionRX Metrics

BasicAdvanced
$58M
Market cap
-
P/E ratio
-$0.46
EPS
1.17
Beta
-
Dividend rate
$58M
1.17032
$1.79
$0.55
199K
0.428
-173.85%
-188.25%
73.334
133.06%
16.59%
286.48%

What the Analysts think about VolitionRX

Analyst Ratings

Majority rating from 3 analysts.
Buy

VolitionRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-8,300.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$100K
-50.00%
Net income
-$8.3M
-3.49%
Profit margin
-8,300.00%
93.02%

VolitionRX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.09%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.14
-$0.11
-$0.11
-$0.10
-
Expected
-$0.15
-$0.13
-$0.11
-$0.11
-$0.10
Surprise
-5.08%
-15.38%
3.12%
-9.09%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for VolitionRX stock?

VolitionRX (VNRX) has a market cap of $58M as of June 20, 2024.

What is the P/E ratio for VolitionRX stock?

The price to earnings (P/E) ratio for VolitionRX (VNRX) stock is 0 as of June 20, 2024.

Does VolitionRX stock pay dividends?

No, VolitionRX (VNRX) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next VolitionRX dividend payment date?

VolitionRX (VNRX) stock does not pay dividends to its shareholders.

What is the beta indicator for VolitionRX?

VolitionRX (VNRX) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the VolitionRX stock price target?

The target price for VolitionRX (VNRX) stock is $3.73, which is NaN% below the current price of $. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell VolitionRX stock

Buy or sell VolitionRX stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing